Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts

被引:0
|
作者
Hu, Xianwen [1 ]
Hu, Hongyu [1 ]
Li, Dandan [2 ]
Wang, Pan [1 ]
Cai, Jiong [1 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Nucl Med, 149 Dalian Rd, Zunyi 563003, Peoples R China
[2] Zunyi Hosp Tradit Chinese Med, Dept Obstet, Zunyi 563003, Guizhou, Peoples R China
来源
OPEN MEDICINE | 2024年 / 19卷 / 01期
关键词
human epidermal growth factor receptor 2; affibody; SPECT imaging; ovarian cancer; Tc-99m; BIODISTRIBUTION;
D O I
10.1515/med-2024-1027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose- This study aimed to assess the biodistribution and bioactivity of the affibody molecular probe Tc-99m-(HE)(3)Z(HER2:V2), prepared by genetic recombination, and to investigate its potential for targeted human epidermal growth factor receptor 2 (HER2) imaging in SKOV3 ovarian cancer and MDA-MB-361 breast cancer xenografts. Methods- Affibody molecules were generated through genetic recombination. The radiochemical purity of the Tc-99m-labeled HER2 affibody was determined using reverse phase high performance liquid chromatography (RP-HPLC). Evaluation of HER2 affinity in SKOV3 ovarian cancer cells and MDA-MB-361 breast cancer cells (HER2-positive) was conducted by calculating equilibrium dissociation constants. Biodistribution of the Tc-99m-labeled affibody molecular probe was assessed in Balb/c mice bearing SKOV3 tumors. Tumor targeting specificity was evaluated in Balb/c mice using SKOV3, MDA-MB-361, and AT-3 (HER2-negative) xenografts. Results- Affibody (HE)(3)Z(HER2:V2), generated through recombinant gene expression, was successfully labeled with Tc-99m, achieving a radiochemical purity of (96.0 +/- 1.7)% (n = 3) as determined by RP-HPLC. This molecular probe exhibited specific binding to HER2-positive SKOV3 cells, demonstrating intense radioactive uptake. Biodistribution analysis showed rapid accumulation of Tc-99m-(HE)(3)Z(HER2:V2) in HER2-positive tumors post-administration, primarily clearing through the urinary system. Single-photon emission computed tomography imaging conducted 1-3 h after intravenous injection of Tc-99m-(HE)(3)Z(HER2:V2) into HER2-positive SKOV3 and MDA-MB-361 nude mouse models confirmed targeted uptake of the molecular probe by the tumors. Conclusions- The molecular probe Tc-99m-(HE)(3)Z(HER2:V2) developed in this study effectively targets HER2 for imaging HER2-positive SKOV3 and MDA-MB-361 xenografts in vivo. It exhibits rapid blood clearance without evident toxic effects, suggesting its potential as a valuable marker for detecting HER2 expression in tumor cells.
引用
收藏
页数:10
相关论文
共 13 条
  • [1] Radiosynthesis, optimization and pharmacokinetic study of the 99mTc-labeled human epidermal growth factor receptor 2 affibody molecule probe 99mTc-(HE)3ZHER2:V2
    Hu, Xianwen
    Liang, Zhigang
    Qi, Lili
    Li, Fangming
    Cai, Xiaojia
    Cai, Jiong
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (04) : 244 - 251
  • [2] Non-Invasive Monitoring of HER2 Expression in Breast Cancer Patients with 99mTc-Affibody SPECT/CT
    Cai, Jiong
    Li, Xin
    Mao, Feng
    Wang, Pan
    Luo, Yaping
    Zheng, Kun
    Li, Fang
    Zhu, Zhaohui
    IRANIAN JOURNAL OF RADIOLOGY, 2020, 17 (01)
  • [3] Preclinical evaluation of 99mTc direct labeling ZHER2:V2 for HER2 positive tumors imaging
    Yang, Yang
    Zhao, Xinming
    Xing, Yu
    Yu, Tianying
    Zhang, Jingmian
    Wang, Jianfang
    ONCOLOGY LETTERS, 2018, 16 (04) : 5361 - 5366
  • [4] Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
    Bragina, Olga
    Chernov, Vladimir
    Schulga, Alexey
    Konovalova, Elena
    Garbukov, Eugeniy
    Vorobyeva, Anzhelika
    Orlova, Anna
    Tashireva, Liubov
    Sorensen, Jens
    Zelchan, Roman
    Medvedeva, Anna
    Deyev, Sergey
    Tolmachev, Vladimir
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (04) : 528 - 535
  • [5] Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
    Han, Jingya
    Chen, Yang
    Zhao, Yan
    Zhao, Xinming
    Zhang, Jingmian
    Wang, Jianfang
    Zhang, Zhaoqi
    FRONTIERS IN MEDICINE, 2022, 9
  • [6] Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer
    Bragina, Olga
    Chernov, Vladimir
    Larkina, Mariia
    Rybina, Anstasiya
    Zelchan, Roman
    Garbukov, Eugeniy
    Oroujeni, Maryam
    Loftenius, Annika
    Orlova, Anna
    Soerensen, Jens
    Frejd, Fredrik Y.
    Tolmachev, Vladimir
    THERANOSTICS, 2023, 13 (14): : 4858 - 4871
  • [7] Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
    Bragina, Olga
    von Witting, Emma
    Garousi, Javad
    Zelchan, Roman
    Sandstrom, Mattias
    Orlova, Anna
    Medvedeva, Anna
    Doroshenko, Artem
    Vorobyeva, Anzhelika
    Lindbo, Sarah
    Borin, Jesper
    Tarabanovskaya, Natalya
    Sorensen, Jens
    Hober, Sophia
    Chernov, Vladimir
    Tolmachev, Vladimir
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 493 - 499
  • [8] Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [99mTc] Tc-Labeled Small Peptide
    Ardakani, Javad Biabani
    Abedi, Seyed Mohammad
    Mardanshahi, Alireza
    Shojaee, Leyla
    Zaboli, Ehsan
    Khorramimoghaddam, Alireza
    Nosrati, Anahita
    Sabahno, Hamideh
    Banimostafavi, Elahm Sadat
    Hosseinimehr, Seyed Jalal
    CLINICAL BREAST CANCER, 2023, 23 (02) : 219 - 230
  • [9] Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study
    Shi, Jiyun
    Du, Shuaifan
    Wang, Rongxi
    Gao, Hannan
    Luo, Qi
    Hou, Guozhu
    Zhou, Yidong
    Zhu, Zhaohui
    Wang, Fan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [10] Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
    Zhao, Lingzhou
    Xing, Yan
    Liu, Changcun
    Ma, Shaofei
    Huang, Wenhua
    Cheng, Zhen
    Zhao, Jinhua
    BREAST CANCER RESEARCH, 2024, 26 (01)